152-160, City Road, EC1V 2NX London
United Kingdom of Great Britain and Northern Ireland
Telephone +44 333 5775210
sales@speedx.com.au
http://www.plexpcr.com
Product Categories
Product categories
03 Diagnostic Tests
03.06 Genetic testing, molecular diagnostics
03.06.01 DNA testing
DNA testing
03 Diagnostic Tests
03.06 Genetic testing, molecular diagnostics
03.06.03 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR)
Our products
Product category: DNA testing, Polymerase chain reaction (PCR)
PlexPCR® VHS
PlexPCR VHS* is a multiplex qPCR test for detection and differentiation of HSV-1, HSV-2, VZV & Treponema pallidum
(Syphilis) from genital and non-genital swabs. Proprietary PlexZyme® technology provides 4-levels of specificity and market-leading performance to streamline your lesion testing workflow.Challenges of lesion diagnostics
Product category: DNA testing, Polymerase chain reaction (PCR)
ResistancePlus GC
ResistancePlus GC* is a multiplex qPCR test for detection of Neisseria gonorrhoeae and sequences linked to ciprofloxacin susceptibility, validated for a range of specimen types. Dual N. gonorrhoeae targets improve clinical specificity. Ciprofloxacin resistance and susceptibility targets are included for additional confidence. ResistancePlus GC* is powered by proprietary PlexPCR® technologies demonstrating improved multiplex performance compared with other probe-based tests.
Product category: DNA testing, Polymerase chain reaction (PCR)
ResistancePlus MG
ResistancePlus MG* is a multiplex qPCR test for detection of Mycoplasma genitalium and five macrolide resistance markers from male and female urine and swab specimens. Proprietary PlexZyme® and PlexPrime® technologies improve multiplex performance compared with other probe-based tests allowing for multiple mutation detection in a single well.
ad: contact information
About Us
Company details
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
SpeeDx Vision
To innovate clinical diagnostic approaches for improved delivery, reduced costs, and better patient outcome.
SpeeDx Mission
Empowering practitioners to make informed clinical decisions for improved patient outcomes.
SpeeDx Quality Policy
SpeeDx has a quality mission to consistently meet the needs and expectations of customers, commercial partners, and regulators in the following way:
SpeeDx will comply with ISO 13485, IVDD (EU), QSR (US FDA), MDR (Health Canada), TGR 2002 (Australian TGA) and any other regulatory requirements as they arise; our Quality System effectiveness will be reviewed and maintained by management.
SpeeDx will endeavour to improve the health and safety of customers by continuing to invest in product development activities with the aim of producing in vitro diagnostic medical devices and research use only products for the detection of nucleic acids.
A company-wide culture committed to quality will be supported by management with the establishment and continuous review of quality objectives.
Achievement of this goal involves all staff, each of whom are individually responsible for the quality of their work, resulting in a continually improving work environment and a continually improving Quality Management System. Management at every level has an additional responsibility to ensure quality is instilled in all levels of the organisation, and in all activities.
ad: company
SOE Health LtdSony Europe B.V.
Speed Plastics Ltd.
Spirit Healthcare Limited
Starna Scientific Ltd.
STERIS